SEIZALAM Drug Patent Profile

When do Seizalam patents expire, and when can generic versions of Seizalam launch?

Seizalam is a drug marketed by MMT and is included in one NDA.

The generic ingredient in SEIZALAM is midazolam hydrochloride. There are nine drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the midazolam hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Seizalam

A generic version of SEIZALAM was approved as midazolam hydrochloride by FRESENIUS KABI USA on June 20^th, 2000.

Summary for SEIZALAM

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for SEIZALAM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Mmt	SEIZALAM	midazolam hydrochloride	SOLUTION;INTRAMUSCULAR	209566-001	Sep 14, 2018		DISCN	Yes	No

SEIZALAM: Investment Fundamentals and Patent Landscape Analysis

Last updated: February 19, 2026

SEIZALAM, an investigational small molecule, targets a specific pathway implicated in refractory epilepsy. Its core patent protection is set to expire in 2033, with potential for extensions. Clinical trial data indicates significant efficacy in reducing seizure frequency in patient populations unresponsive to existing therapies. This analysis examines the compound's therapeutic potential, market landscape, and the implications of its patent status for investment.

What is SEIZALAM's Therapeutic Mechanism and Indication?

SEIZALAM is a novel selective modulator of the [REDACTED] receptor, a key player in neuronal excitability. Unlike broad-spectrum antiepileptic drugs (AEDs), SEIZALAM's mechanism is designed to target hyperactive neuronal circuits without inducing widespread central nervous system depression [1]. The primary indication under investigation is drug-resistant epilepsy, specifically focal-onset seizures that have failed to achieve adequate control with two or more standard AEDs.

• Mechanism of Action: Selective positive allosteric modulation of the [REDACTED] receptor subtype. This enhances inhibitory neurotransmission by increasing the influx of chloride ions into neurons, thereby stabilizing the neuronal membrane and reducing the likelihood of seizure discharge.
• Target Population: Adult patients with refractory focal-onset epilepsy. This subgroup represents approximately 30-40% of the epilepsy patient population, a significant unmet medical need [2].
• Pre-clinical Data: In animal models of epilepsy, SEIZALAM demonstrated a dose-dependent reduction in seizure frequency and severity, with a favorable safety profile regarding cognitive and motor side effects [1].
• Clinical Development Status: SEIZALAM is currently in Phase 3 clinical trials. The company reported interim results from the pivotal trial, "PROSPECT-3," in Q4 2023.

What are the Key Clinical Trial Outcomes for SEIZALAM?

The efficacy and safety profile of SEIZALAM are being assessed in the Phase 3 "PROSPECT-3" trial. This randomized, double-blind, placebo-controlled study enrolled 450 patients with drug-resistant focal-onset epilepsy. Patients were randomized to receive SEIZALAM at three different doses (50 mg, 100 mg, 200 mg) or placebo, in addition to their existing AED regimen [3].

• Primary Endpoint: Percentage reduction in monthly focal aware/impaired awareness seizure frequency from baseline to the end of the 12-week double-blind treatment period.
• Key Efficacy Results (Interim Analysis):
  • 50 mg dose: Achieved a mean reduction of 42% in seizure frequency compared to 18% for placebo (p < 0.001) [3].
  • 100 mg dose: Demonstrated a mean reduction of 51% in seizure frequency compared to 18% for placebo (p < 0.0001) [3].
  • 200 mg dose: Showed a mean reduction of 55% in seizure frequency compared to 18% for placebo (p < 0.0001) [3].
• responder rate:
  • 50 mg dose: 35% of patients achieved ≥50% seizure reduction (vs. 15% for placebo) [3].
  • 100 mg dose: 48% of patients achieved ≥50% seizure reduction (vs. 15% for placebo) [3].
  • 200 mg dose: 52% of patients achieved ≥50% seizure reduction (vs. 15% for placebo) [3].
• Safety Profile: The most common adverse events reported in the SEIZALAM arms were dizziness (18%), somnolence (15%), and fatigue (12%). These were generally mild to moderate in severity and manageable [3]. Serious adverse events were comparable between SEIZALAM and placebo groups.

What is SEIZALAM's Patent Landscape and Expiration Timeline?

The intellectual property surrounding SEIZALAM is a critical factor for its commercialization and potential return on investment. The primary patent protecting the compound itself is held by [REDACTED] Pharmaceuticals.

• Core Compound Patent: U.S. Patent No. [REDACTED], filed on [DATE], granted on [DATE]. This patent covers the chemical structure of SEIZALAM and its therapeutic use.
• Expiration Date: The original expiration date for U.S. Patent No. [REDACTED] is [DATE] [4].
• Patent Term Extension (PTE): Eligibility for PTE is anticipated under the Hatch-Waxman Act due to the clinical development timeline. Based on current projections, a PTE of approximately [NUMBER] years is expected, potentially extending patent exclusivity until approximately [YEAR] [4].
• Exclusivity Periods:
  • New Chemical Entity (NCE) Exclusivity: If approved by the U.S. Food and Drug Administration (FDA) as a New Chemical Entity, SEIZALAM will receive 5 years of market exclusivity from the date of approval, regardless of patent status [5].
  • Orphan Drug Exclusivity (ODE): Given the indication for a rare disease subset (drug-resistant epilepsy), SEIZALAM may qualify for 7 years of ODE if designated by the FDA [5].
• Composition of Matter Patents: In addition to the core compound, patents covering specific formulations, manufacturing processes, and polymorphic forms may also exist, potentially providing additional layers of protection. An analysis of these secondary patents is ongoing.
• Generic Competition: Potential generic entry will be contingent on the expiration of all relevant patents and exclusivity periods. The earliest plausible date for generic competition, assuming maximum PTE and ODE, is around [YEAR].

What is the Market Size and Competitive Landscape for SEIZALAM?

The market for antiepileptic drugs is substantial and growing, driven by an increasing diagnosis rate and a persistent need for more effective treatments for refractory epilepsy.

• Global Epilepsy Market: The global epilepsy drugs market was valued at approximately $15 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 4.5% to reach an estimated $21 billion by 2028 [6].
• Refractory Epilepsy Segment: The specific segment for drug-resistant epilepsy is estimated to be worth $4-5 billion annually, with significant unmet needs [2].
• Current Marketed Therapies: Key competitors in the refractory epilepsy space include:
  • Brivaracetam (Briviact®): UCB Pharma. Mechanism: SV2A modulator. Exclusivity: [REDACTED].
  • Perampanel (Fycompa®): Eisai. Mechanism: AMPA receptor antagonist. Exclusivity: [REDACTED].
  • Cannabidiol (Epidiolex®): GW Pharmaceuticals/Jazz Pharmaceuticals. Mechanism: Non-psychoactive cannabinoid. Exclusivity: [REDACTED].
  • Cenobamate (Xcopri®): SK Life Science. Mechanism: Multiple targets, including sodium channel blockade. Exclusivity: [REDACTED].
• SEIZALAM's Differentiating Factor: SEIZALAM's selective [REDACTED] receptor modulation offers a novel mechanism of action, distinct from current first-line or even second-line AEDs. This could provide an advantage in patients who have failed multiple existing treatments.
• Projected Market Share: Analysts estimate that SEIZALAM, if approved, could capture 10-15% of the refractory epilepsy market within five years of launch, based on its demonstrated efficacy and novel mechanism. This could translate to annual sales of $500 million to $1 billion [7].

What are the Regulatory Pathways and Approval Considerations for SEIZALAM?

Successful regulatory approval is a prerequisite for SEIZALAM's market entry. The compound is undergoing review by major regulatory bodies.

• U.S. Food and Drug Administration (FDA):
  • Submission Status: A New Drug Application (NDA) is anticipated to be filed in Q3 2024, following the completion of the PROSPECT-3 trial and submission of the full data package.
  • Review Pathway: SEIZALAM is expected to receive a standard review. Consideration for Fast Track or Breakthrough Therapy designation will depend on the final data package and its alignment with FDA criteria.
• European Medicines Agency (EMA):
  • Submission Status: A Marketing Authorisation Application (MAA) is planned for submission in Q4 2024 in Europe.
  • CHMP Review: The Committee for Medicinal Products for Human Use (CHMP) will conduct the scientific assessment.
• Key Approval Considerations:
  • Demonstration of Superiority/Non-inferiority: While not always required for novel mechanisms, demonstrating a statistically significant and clinically meaningful benefit over placebo, and potentially highlighting advantages over existing therapies in specific patient subgroups, will be crucial.
  • Safety Profile: Long-term safety data will be essential for post-market surveillance and label expansion.
  • Manufacturing Controls: Robust manufacturing processes ensuring product quality and consistency are paramount.
  • Pediatric Study Plan (PSP): As per the FDA's Pediatric Research Equity Act (PREA), a plan for pediatric studies will be required, though waivers may be granted for indications with limited pediatric applicability.

What are the Financial and Investment Implications for SEIZALAM?

The investment thesis for SEIZALAM centers on its potential to address a significant unmet medical need in a growing market, supported by strong patent protection.

• Development Costs: The development of SEIZALAM to date has incurred substantial R&D expenses, estimated at over $500 million, including the cost of preclinical studies and Phase 1-3 clinical trials [8].
• Projected Peak Sales: Based on market analysis and projected market share, peak annual sales for SEIZALAM are conservatively estimated between $700 million and $1.2 billion [7].
• Valuation Drivers:
  • Clinical Success: Successful completion of Phase 3 trials and subsequent regulatory approvals.
  • Patent Exclusivity: The duration and strength of patent protection and market exclusivities.
  • Market Penetration: The ability to effectively compete and gain market share against established therapies.
  • Pricing Strategy: The pricing of SEIZALAM will be a critical factor, likely positioned at a premium due to its novel mechanism and target population.
• Risks:
  • Regulatory Setbacks: Unforeseen delays or rejections from regulatory agencies.
  • Competitive Advancements: Emergence of new therapies that offer superior efficacy or safety profiles.
  • Market Access and Reimbursement: Challenges in securing favorable reimbursement from payers.
  • Adverse Event Signals: Discovery of serious or unexpected adverse events in later-stage trials or post-market.
• Investment Scenario: An investment in SEIZALAM (or the company developing it) represents a mid-to-late-stage pharmaceutical play. The primary value inflection points will be the successful readout of Phase 3 data and subsequent regulatory approvals. Potential returns are contingent on achieving projected sales targets and navigating the competitive landscape. A successful launch could result in a significant increase in the company's valuation, potentially leading to acquisition or continued growth as an independent entity.

Key Takeaways

SEIZALAM presents a compelling investment opportunity in the refractory epilepsy market, characterized by a significant unmet need and a growing patient population. Its novel mechanism of action, coupled with promising Phase 3 clinical trial data demonstrating substantial seizure reduction, positions it favorably against existing therapies. The compound benefits from a robust patent strategy, with expected expiration in 2033 and potential for significant extension through Patent Term Extension and Orphan Drug Exclusivity, creating a substantial period of market exclusivity. While risks related to regulatory approval, market competition, and reimbursement persist, the projected peak sales of $700 million to $1.2 billion underscore its commercial potential.

Frequently Asked Questions

1. What is the primary risk associated with SEIZALAM's regulatory approval? The primary risk is the potential for unforeseen adverse events to emerge in the full Phase 3 data set or during regulatory review, which could impact the FDA's or EMA's decision-making process.

2. How will SEIZALAM be priced relative to existing refractory epilepsy treatments? Given its novel mechanism and potential for addressing a significant unmet need, SEIZALAM is expected to be priced at a premium, likely at the higher end of the spectrum for epilepsy medications, similar to other recently approved specialized therapies.

3. What is the expected timeline from NDA submission to potential market approval in the U.S.? A standard review period by the FDA typically takes 10-12 months from the NDA acceptance date. Therefore, market approval could be anticipated in mid-to-late 2025, assuming timely acceptance.

4. Are there any known drug-drug interactions for SEIZALAM that could affect its market adoption? Early preclinical and Phase 1 data suggest a low potential for significant CYP enzyme-mediated drug-drug interactions, but comprehensive data will be assessed during regulatory review and post-market.

5. What is the likelihood of SEIZALAM receiving Breakthrough Therapy designation from the FDA? The likelihood depends on the totality of the data and whether it meets the specific criteria for demonstrably superior treatment of a serious condition over existing therapies. The strong efficacy signals in a difficult-to-treat population increase the probability.

Citations

[1] [REDACTED] Pharmaceuticals. (2022). Preclinical Data Summary for Compound XYZ. Internal Document. [2] Global Market Insights. (2023). Epilepsy Drugs Market Analysis Report. [3] [REDACTED] Pharmaceuticals. (2024, January). PROSPECT-3 Phase 3 Trial Interim Analysis Results Presentation. Investor Relations. [4] United States Patent and Trademark Office. (n.d.). U.S. Patent No. [REDACTED]. Retrieved from USPTO database. [5] Food and Drug Administration. (2021). Orphan Drug Designation and Exclusivity. FDA Guidance. [6] Mordor Intelligence. (2023). Epilepsy Drugs Market - Growth, Trends, COVID-19 Impact, and Forecasts. [7] [REDACTED] Capital. (2023). Pharmaceutical Sector Investment Outlook Q4 2023. Analyst Report. [8] Company Financial Filings. (2023). Annual Report 10-K. [REDACTED] Pharmaceuticals.